Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Escherichia colistrains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia

Authors: Darina Kohoutova, David Smajs, Paula Moravkova, Jiri Cyrany, Monika Moravkova, Miroslava Forstlova, Michal Cihak, Stanislav Rejchrt, Jan Bures

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Colorectal cancer (CRC) is the 3rd most common cancer worldwide and the Czech Republic has the 6th highest incidence of CRC worldwide. Large intestinal microbiota play in its etiopathogenesis important role. Bacteriocins are proteins, produced by bacteria from the Enterobacteriaceae family. The aim of our prospective study was to assess the colonization of large intestinal mucosa by Escherichia coli strains and to investigate their bacteriocin production.

Methods

A total of 30 consecutive patients with colorectal adenoma, CRA (17 men, 13 women, aged 39–79, mean age 63 ± 9), 30 patients with CRC (23 men, 7 women, aged 38–86, mean age 67 ± 11) and 20 healthy controls (9 men, 11 women, age 23–84, mean age 55 ± 15) were enrolled into prospective study. Mucosal biopsies were taken in the caecum, transverse colon and rectum during pancolonoscopy. Microbiological culture, isolation and identification of bacteria followed. Bacteriocin production was assessed by growth inhibition of indicator strains E. coli K12-Row, E. coli C6 (phi), and Shigella sonnei 17. Identification of bacteriocin-encoding determinants and E. coli phylogroups was performed using PCR methods.

Results

A total of 622 strains were isolated and further investigated. A significantly higher frequency of simultaneous production of colicins and microcins was revealed in the group of patients with CRC, when compared to patients with CRA, p = 0.031. A significantly higher frequency of E. coli phylogroup D was found in patients with CRC, when compared to controls, p = 0.044. A significantly higher prevalence of bacteriocinogeny was confirmed in patients with advanced adenoma when compared to patients with non-advanced adenoma, p = 0.010. Increasing bacteriocinogeny was associated with an increasing stage of CRC (assessed according to TNM classification). Either E. coli phylogroup B2 or E. coli phylogroup D were isolated in biopsies of patients with right-sided CRC. A statistically higher incidence of E. coli phylogroup B2 was found in patients with right-sided CRC when compared to patients with left-sided CRC, p = 0.028.

Conclusions

Large intestinal mucosa of patients with more advanced colorectal neoplasia is colonized with more virulent strains of E. coli and higher production of bacteriocins is observed in these patients when compared to those with less advanced colorectal neoplasia.
Appendix
Available only for authorised users
Literature
2.
go back to reference Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD: The gut microbiome modulates colon tumorigenesis. MBio. 2013, 4: e00692-13. 10.1128/mBio.00692-13.CrossRefPubMedPubMedCentral Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD: The gut microbiome modulates colon tumorigenesis. MBio. 2013, 4: e00692-13. 10.1128/mBio.00692-13.CrossRefPubMedPubMedCentral
3.
go back to reference Yang T, Owen JL, Lightfoot YL, Kladde MP, Mohamadzadeh M: Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med. 2013, 19: 714-725. 10.1016/j.molmed.2013.08.005.CrossRefPubMed Yang T, Owen JL, Lightfoot YL, Kladde MP, Mohamadzadeh M: Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med. 2013, 19: 714-725. 10.1016/j.molmed.2013.08.005.CrossRefPubMed
4.
go back to reference Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G, Berretta M: Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs. 2013, 24: 1069-1078. 10.1097/CAD.0000000000000002.CrossRefPubMed Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, Cavaliere C, Nasti G, Facchini G, Berretta M: Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs. 2013, 24: 1069-1078. 10.1097/CAD.0000000000000002.CrossRefPubMed
5.
go back to reference Rahman AU, Salajegheh A, Smith RA, Lam AK: BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects. Curr Cancer Drug Targets, in press., Rahman AU, Salajegheh A, Smith RA, Lam AK: BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects. Curr Cancer Drug Targets, in press.,
6.
go back to reference Brown CL, Smith K, McCaughey L, Walker D: Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. Biochem Soc Trans. 2012, 40: 1549-1552. 10.1042/BST20120241.CrossRefPubMed Brown CL, Smith K, McCaughey L, Walker D: Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. Biochem Soc Trans. 2012, 40: 1549-1552. 10.1042/BST20120241.CrossRefPubMed
7.
go back to reference Chumchalová J, Smarda J: Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003, 48: 111-115. 10.1007/BF02931286.CrossRef Chumchalová J, Smarda J: Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003, 48: 111-115. 10.1007/BF02931286.CrossRef
8.
go back to reference Messaoudi S, Manai M, Kergourlay G, Prévost H, Connil N, Chobert JM, Dousset X: Lactobacillus salivarius: bacteriocin and probiotic activity. Food Microbiol. 2013, 36: 296-304. 10.1016/j.fm.2013.05.010.CrossRefPubMed Messaoudi S, Manai M, Kergourlay G, Prévost H, Connil N, Chobert JM, Dousset X: Lactobacillus salivarius: bacteriocin and probiotic activity. Food Microbiol. 2013, 36: 296-304. 10.1016/j.fm.2013.05.010.CrossRefPubMed
9.
go back to reference Farkas-Himsley H, Yu H: Purified colicin as cytotoxic agent of neoplasia: comparative study with crude colicin. Cytobios. 1985, 42: 193-207.PubMed Farkas-Himsley H, Yu H: Purified colicin as cytotoxic agent of neoplasia: comparative study with crude colicin. Cytobios. 1985, 42: 193-207.PubMed
10.
go back to reference Musclow E, Farkas-Himsley H: Bacteriocin and flow cytometry in laboratory diagnosis of leukemic peripheral blood lymphocytes and bone marrow cells. Eur J Cancer Clin Oncol. 1983, 19: 163-171. 10.1016/0277-5379(83)90413-3.CrossRefPubMed Musclow E, Farkas-Himsley H: Bacteriocin and flow cytometry in laboratory diagnosis of leukemic peripheral blood lymphocytes and bone marrow cells. Eur J Cancer Clin Oncol. 1983, 19: 163-171. 10.1016/0277-5379(83)90413-3.CrossRefPubMed
11.
go back to reference Cornut G, Fortin C, Soulières D: Antineoplastic properties of bacteriocins: revisiting potential active agents. Am J Clin Oncol. 2008, 31: 399-404. 10.1097/COC.0b013e31815e456d.CrossRefPubMed Cornut G, Fortin C, Soulières D: Antineoplastic properties of bacteriocins: revisiting potential active agents. Am J Clin Oncol. 2008, 31: 399-404. 10.1097/COC.0b013e31815e456d.CrossRefPubMed
12.
go back to reference Bures J, Horák V, Fixa B, Komárková O, Zaydlar K, Lonský V, Masurka V: Colicinogeny in colorectal cancer. Neoplasma. 1986, 33: 233-237.PubMed Bures J, Horák V, Fixa B, Komárková O, Zaydlar K, Lonský V, Masurka V: Colicinogeny in colorectal cancer. Neoplasma. 1986, 33: 233-237.PubMed
13.
go back to reference Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M, Slatin S, Cavard D: Colicin biology. Microbiol Mol Biol Rev. 2007, 71: 158-229. 10.1128/MMBR.00036-06.CrossRefPubMedPubMedCentral Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M, Slatin S, Cavard D: Colicin biology. Microbiol Mol Biol Rev. 2007, 71: 158-229. 10.1128/MMBR.00036-06.CrossRefPubMedPubMedCentral
14.
go back to reference Bures J, Smajs D, Kvetina J, Forstl M, Smarda J, Kohoutova D, Kunes M, Cyrany J, Tacheci I, Rejchrt S, Lesna J, Vorisek V, Kopacova M: Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol. 2011, 17: 609-617. 10.3748/wjg.v17.i5.609.CrossRefPubMedPubMedCentral Bures J, Smajs D, Kvetina J, Forstl M, Smarda J, Kohoutova D, Kunes M, Cyrany J, Tacheci I, Rejchrt S, Lesna J, Vorisek V, Kopacova M: Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol. 2011, 17: 609-617. 10.3748/wjg.v17.i5.609.CrossRefPubMedPubMedCentral
15.
go back to reference Smajs D, Micenkova L, Smarda J, Vrba M, Sevcíkova A, Valisova Z, Woznicova V: Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor. BMC Microbiol. 2010, 10: 288-10.1186/1471-2180-10-288.CrossRefPubMedPubMedCentral Smajs D, Micenkova L, Smarda J, Vrba M, Sevcíkova A, Valisova Z, Woznicova V: Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor. BMC Microbiol. 2010, 10: 288-10.1186/1471-2180-10-288.CrossRefPubMedPubMedCentral
16.
go back to reference Russo TA, Johnson JR: Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis. 2000, 181: 1753-1754. 10.1086/315418.CrossRefPubMed Russo TA, Johnson JR: Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis. 2000, 181: 1753-1754. 10.1086/315418.CrossRefPubMed
17.
go back to reference Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A: Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014, 20: 859-867. 10.1158/1078-0432.CCR-13-1343.CrossRefPubMed Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A: Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014, 20: 859-867. 10.1158/1078-0432.CCR-13-1343.CrossRefPubMed
18.
go back to reference Lee S, Yu JK, Park K, Oh EJ, Kim SY, Park YJ: Phylogenetic groups and virulence factors in pathogenic and commensal strains of Escherichia coli and their association with blaCTX-M. Ann Clin Lab Sci. 2010, 40: 361-367.PubMed Lee S, Yu JK, Park K, Oh EJ, Kim SY, Park YJ: Phylogenetic groups and virulence factors in pathogenic and commensal strains of Escherichia coli and their association with blaCTX-M. Ann Clin Lab Sci. 2010, 40: 361-367.PubMed
19.
go back to reference Sobieszczańska BA, Duda-Madej AB, Turniak MB, Franiczek R, Kasprzykowska U, Duda AK, Rzeszutko M, Iwańczak B: Invasive properties, adhesion patterns and phylogroup profiles among Escherichia coli strains isolated from children with inflammatory bowel disease. Adv Clin Exp Med. 2012, 21: 591-599.PubMed Sobieszczańska BA, Duda-Madej AB, Turniak MB, Franiczek R, Kasprzykowska U, Duda AK, Rzeszutko M, Iwańczak B: Invasive properties, adhesion patterns and phylogroup profiles among Escherichia coli strains isolated from children with inflammatory bowel disease. Adv Clin Exp Med. 2012, 21: 591-599.PubMed
20.
go back to reference Nowrouzian FL, Oswald E: Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog. 2012, 53: 180-182. 10.1016/j.micpath.2012.05.011.CrossRefPubMed Nowrouzian FL, Oswald E: Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog. 2012, 53: 180-182. 10.1016/j.micpath.2012.05.011.CrossRefPubMed
21.
go back to reference Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP: Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010, 107: 11537-11542. 10.1073/pnas.1001261107.CrossRefPubMedPubMedCentral Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP: Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010, 107: 11537-11542. 10.1073/pnas.1001261107.CrossRefPubMedPubMedCentral
22.
go back to reference Secher T, Samba-Louaka A, Oswald E, Nougayrède JP: Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PLoS One. 2013, 8: e77157-10.1371/journal.pone.0077157.CrossRefPubMedPubMedCentral Secher T, Samba-Louaka A, Oswald E, Nougayrède JP: Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PLoS One. 2013, 8: e77157-10.1371/journal.pone.0077157.CrossRefPubMedPubMedCentral
23.
go back to reference Cougnoux A, Gibold L, Robin F, Dubois D, Pradel N, Darfeuille-Michaud A, Dalmasso G, Delmas J, Bonnet R: Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP. J Mol Biol. 2012, 424: 203-214. 10.1016/j.jmb.2012.09.017.CrossRefPubMed Cougnoux A, Gibold L, Robin F, Dubois D, Pradel N, Darfeuille-Michaud A, Dalmasso G, Delmas J, Bonnet R: Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP. J Mol Biol. 2012, 424: 203-214. 10.1016/j.jmb.2012.09.017.CrossRefPubMed
24.
go back to reference Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R: High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One. 2013, 8: e56964-10.1371/journal.pone.0056964.CrossRefPubMedPubMedCentral Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R: High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One. 2013, 8: e56964-10.1371/journal.pone.0056964.CrossRefPubMedPubMedCentral
25.
go back to reference Hansen IO, Jess P: Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012, 59: A4444-PubMed Hansen IO, Jess P: Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012, 59: A4444-PubMed
26.
go back to reference Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012, 338: 120-123. 10.1126/science.1224820.CrossRefPubMedPubMedCentral Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012, 338: 120-123. 10.1126/science.1224820.CrossRefPubMedPubMedCentral
27.
go back to reference Fuska J, Fusková A, Smarda J, Mach J: Effect of colicin E3 on leukemia cells P388 in vitro. Experientia. 1979, 35: 406-407. 10.1007/BF01964380.CrossRefPubMed Fuska J, Fusková A, Smarda J, Mach J: Effect of colicin E3 on leukemia cells P388 in vitro. Experientia. 1979, 35: 406-407. 10.1007/BF01964380.CrossRefPubMed
28.
go back to reference Mittelman M, Farkas-Himsley H, Haran-Ghera N: Recognition of T-cell murine leukemia by bacteriocin (colicin); correlation with transplantation experiments. Leuk Res. 1987, 11: 215-222. 10.1016/0145-2126(87)90045-2.CrossRefPubMed Mittelman M, Farkas-Himsley H, Haran-Ghera N: Recognition of T-cell murine leukemia by bacteriocin (colicin); correlation with transplantation experiments. Leuk Res. 1987, 11: 215-222. 10.1016/0145-2126(87)90045-2.CrossRefPubMed
29.
go back to reference Smarda J, Obdrzalek V: The lethal effect of colicin E3 on HeLa cells in tissue cultures. IRCS Med Sci. 1977, 5: 524- Smarda J, Obdrzalek V: The lethal effect of colicin E3 on HeLa cells in tissue cultures. IRCS Med Sci. 1977, 5: 524-
30.
go back to reference Smarda J, Obdrzalek V, Taborsky I, Mach J: The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells. Folia Microbiol (Praha). 1978, 23: 272-277. 10.1007/BF02876680.CrossRef Smarda J, Obdrzalek V, Taborsky I, Mach J: The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells. Folia Microbiol (Praha). 1978, 23: 272-277. 10.1007/BF02876680.CrossRef
31.
go back to reference Farkas-Himsley H, Cheung R, Tompkins WAF: Selective antitumor agents: bacteriocins from gram-negative bacteria. IRCS Med Sci. 1975, 3: 149-151. Farkas-Himsley H, Cheung R, Tompkins WAF: Selective antitumor agents: bacteriocins from gram-negative bacteria. IRCS Med Sci. 1975, 3: 149-151.
32.
go back to reference Smarda J, Obdrzalek V: Incidence of colicinogenic strains among human Escherichia coli. J Basic Microbiol. 2001, 41: 367-374. 10.1002/1521-4028(200112)41:6<367::AID-JOBM367>3.0.CO;2-X.CrossRefPubMed Smarda J, Obdrzalek V: Incidence of colicinogenic strains among human Escherichia coli. J Basic Microbiol. 2001, 41: 367-374. 10.1002/1521-4028(200112)41:6<367::AID-JOBM367>3.0.CO;2-X.CrossRefPubMed
Metadata
Title
Escherichia colistrains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia
Authors
Darina Kohoutova
David Smajs
Paula Moravkova
Jiri Cyrany
Monika Moravkova
Miroslava Forstlova
Michal Cihak
Stanislav Rejchrt
Jan Bures
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-014-0733-7

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.